{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:16:14Z","timestamp":1778220974131,"version":"3.51.4"},"reference-count":169,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide, with current treatment modalities frequently limited by tumor heterogeneity and immune evasion. Vaccine-based immunotherapy, particularly that utilizing messenger RNA (mRNA) technology, represents a promising innovative strategy due to its rapid development cycle, generally manageable safety profile in the short term, and potential for personalization. This review examines the limitations of traditional cancer vaccine platforms and contrasts them with the advantages offered by mRNA-based vaccines. It expounds on the various mechanisms through which mRNA vaccines target CRC, such as encoding tumor-associated antigens or tumor-specific neoantigens, delivering immune-stimulating cytokines, and modulating the immunosuppressive tumor microenvironment. An overview of recent clinical trials in the field of mRNA immunotherapy for colorectal cancer is provided. Preliminary evidence from early clinical studies indicates that these approaches exhibit a manageable safety profile and show signs of antitumor activity, showcasing significant potential for clinical application. Furthermore, we also discuss the challenges and prospects that mRNA vaccines are currently facing.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1778522","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:56:08Z","timestamp":1778219768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The evolution of vaccine strategies for colorectal cancer: from conventional approaches to the mRNA era"],"prefix":"10.3389","volume":"17","author":[{"given":"Tengfei","family":"Wang","sequence":"first","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhou","family":"Mei","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songhao","family":"Liu","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenguo","family":"Han","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]},{"name":"Department of Colorectal and Anal Surgery, Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Shanxi Academy of Medical Sciences","place":["Taiyuan, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0189-8","article-title":"Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies","volume":"16","author":"Keum","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103349","article-title":"UBR5 mediates colorectal cancer chemoresistance by attenuating ferroptosis via Lys 11 ubiquitin-dependent stabilization of Smad3-SLC7A11 signaling","volume":"76","author":"Song","year":"2024","journal-title":"Redox Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine\u2013induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1038\/s41467-018-05979-8","article-title":"Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes","volume":"9","author":"Van Hoecke","year":"2018","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68143-9","article-title":"Smallpox","volume":"367","author":"Moore","year":"2006","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1126\/science.abd3377","article-title":"COVID-19 and cancer","volume":"368","author":"Sharpless","year":"2020","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887125","article-title":"mRNA vaccines: the dawn of a new era of cancer immunotherapy","volume":"13","author":"Deng","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.12.5586","article-title":"The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes","volume":"153","author":"Sette","year":"1994","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01945-y","article-title":"Systematic discovery of neoepitope\u2013HLA pairs for neoantigens shared among patients and tumor types","volume":"42","author":"Gurung","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101981","article-title":"An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA\/B \u03b11\/2 shedding","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41392-025-02521-3","article-title":"When vaccines reset tumors: SARS-CoV-2 mRNA shots create a transient checkpoint-sensitive state","volume":"10","author":"Chi","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-024-00305-3","article-title":"Neoantigen-specific mRNA\/DC vaccines for effective anticancer immunotherapy","volume":"25","author":"Zhang","year":"2024","journal-title":"Genes Immun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S198747","article-title":"Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy","volume":"14","author":"Zhang","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2010.02.004","article-title":"Whole tumor antigen vaccines","volume":"22","author":"Chiang","year":"2010","journal-title":"Semin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00262-001-0257-z","article-title":"Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen","volume":"51","author":"Itoh","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2003.10.006","article-title":"Synergistic effect of a granulocyte-macrophage colony-stimulating factor\u2013transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases","volume":"10","author":"Jain","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1200\/JCO.2009.23.3494","article-title":"Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor\u2013secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation","volume":"27","author":"Emens","year":"2009","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.54","article-title":"Prostate cancer vaccines in clinical trials","volume":"11","author":"Lubaroff","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3844-x","article-title":"A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte\u2013macrophage colony stimulating factor\u2013producing bystander cell line in patients with metastatic colorectal cancer","volume":"21","author":"Zheng","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.09.018","article-title":"Phase II study of Vigil\u00ae DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer","volume":"143","author":"Oh","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300642","article-title":"Engineering challenges and opportunities in autologous cellular cancer immunotherapy","volume":"212","author":"Foley","year":"2024","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40425-016-0128-y","article-title":"Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer","volume":"4","author":"Radomski","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669965","article-title":"Autologous dendritic cells in combination with chemotherapy restore responsiveness of T cells in breast cancer patients: A single-arm phase I\/II trial","volume":"12","author":"Bernal-Est\u00e9vez","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1038\/s41467-025-58289-1","article-title":"Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse","volume":"16","author":"Heras-Murillo","year":"2025","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"7211","DOI":"10.1038\/s41467-023-42881-4","article-title":"Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients","volume":"14","author":"Adamik","year":"2023","journal-title":"Nat Commun"},{"key":"B35","article-title":"Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients","volume":"30","author":"Lesterhuis","year":"2010","journal-title":"Anticancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2982","article-title":"Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients","volume":"15","author":"Bonehill","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-135319","article-title":"Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines","volume":"112","author":"Ma","year":"2008","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12967-020-02363-3","article-title":"Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak","volume":"18","author":"Har-Noy","year":"2020","journal-title":"J Transl Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41231-024-00174-y","article-title":"Objective response after immune checkpoint inhibitors in a chemotherapy-refractory pMMR\/MSS metastatic rectal cancer patient primed with experimental AlloStim\u00ae immunotherapy","volume":"9","author":"Hirschfeld","year":"2024","journal-title":"Transl Med Commun"},{"key":"B40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf0685","article-title":"The Human Vaccines Project: A roadmap for cancer vaccine development","volume":"8","author":"Romero","year":"2016","journal-title":"Sci Transl Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1089\/hum.2013.217","article-title":"Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules","volume":"25","author":"Kaufman","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00262-013-1505-8","article-title":"Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma","volume":"63","author":"Bilusic","year":"2013","journal-title":"Cancer Immunology Immunotherapy: CII"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2326-6066.CIR-15-0119","article-title":"Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury","volume":"3","author":"Heery","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/CJI.0000000000000219","article-title":"Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial","volume":"41","author":"Cohn","year":"2018","journal-title":"J Immunotherapy (Hagerstown Md: 1997)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c14690","article-title":"Orally antigen-engineered yeast vaccine elicits robust intestinal mucosal immunity","volume":"19","author":"Chen","year":"2025","journal-title":"ACS Nano"},{"key":"B47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41420-025-02897-9","article-title":"Salmonella typhimurium co-expressing cytolysin A and hyaluronidase suppresses tumor growth and metastasis","volume":"12","author":"Nguyen","year":"2026","journal-title":"Cell Death Discov"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1038\/s41467-024-50950-5","article-title":"Reprogramming the tumor immune microenvironment using engineered dual-drug loaded Salmonella","volume":"15","author":"Nguyen","year":"2024","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40779-022-00416-w","article-title":"Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine","volume":"9","author":"Huang","year":"2022","journal-title":"Mil Med Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004942","article-title":"Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha","volume":"4","author":"Viaud","year":"2009","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12237","article-title":"Neuropilin-1 is present on Foxp3+ T regulatory cell-derived small extracellular vesicles and mediates immunity against skin transplantation","volume":"11","author":"Campos-Mora","year":"2022","journal-title":"J Extracell Vesicles"},{"key":"B52","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70095","article-title":"Exosomes: a double-edged sword in cancer immunotherapy","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm (2020)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-1759(00)00321-5","article-title":"Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry","volume":"247","author":"A","year":"2001","journal-title":"J Immunol Methods"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.1","article-title":"Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer","volume":"16","author":"Dai","year":"2008","journal-title":"Mol Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41541-024-01035-3","article-title":"Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control","volume":"10","author":"Meena","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004043","article-title":"Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents","volume":"10","author":"Turiello","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12218","article-title":"CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment","volume":"11","author":"Lu","year":"2022","journal-title":"J Extracell Vesicles"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2022.07.004","article-title":"Upscaling human mesenchymal stromal cell production in a novel vertical-wheel bioreactor enhances extracellular vesicle secretion and cargo profile","volume":"25","author":"Jeske","year":"2023","journal-title":"Bioact Mater"},{"key":"B60","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-015-0181-x","article-title":"Exosomes in cancer: small particle, big player","volume":"8","author":"Zhang","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41541-025-01118-9","article-title":"Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer","volume":"10","author":"Shah","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0112","article-title":"Safety and activity of PolyPEPI1018 combined with maintenance therapy in metastatic colorectal cancer: an open-label, multicenter, phase Ib study","volume":"28","author":"Hubbard","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-2-19","article-title":"Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer","volume":"2","author":"Tsuruma","year":"2004","journal-title":"J Transl Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0035","article-title":"Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer","volume":"2","author":"Kibe","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.9b00472","article-title":"Peptide-based vaccines: current progress and future challenges","volume":"120","author":"Malonis","year":"2020","journal-title":"Chem Rev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41541-024-00979-w","article-title":"DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma","volume":"9","author":"Neeli","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12060664","article-title":"Advances in nucleic acid universal influenza vaccines","volume":"12","author":"Xu","year":"2024","journal-title":"Vaccines"},{"key":"B69","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/5473","article-title":"The dangers of DNA vaccination","volume":"5","author":"G\u00f3recki","year":"1999","journal-title":"Nat Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s12672-025-02542-y","article-title":"Advances in mRNA vaccine therapy for breast cancer research","volume":"16","author":"Li","year":"2025","journal-title":"Discover Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145130","article-title":"Self-amplifying RNA viruses as RNA vaccines","volume":"21","author":"Lundstrom","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.09.009","article-title":"A trans-amplifying RNA vaccine strategy for induction of potent protective immunity","volume":"28","author":"Beissert","year":"2020","journal-title":"Mol Ther"},{"key":"B74","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-023-06834-7","article-title":"Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides","volume":"625","author":"Huang","year":"2024","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.667","article-title":"Circular RNA-based neoantigen vaccine for hepatocellular carcinoma immunotherapy","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"key":"B76","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1038\/s41467-018-06862-2","article-title":"A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin Transl Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-021-01342-6","article-title":"Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development","volume":"20","author":"Huang","year":"2021","journal-title":"Mol Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1021\/mp100390w","article-title":"In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles","volume":"8","author":"Su","year":"2011","journal-title":"Mol Pharmaceutics"},{"key":"B81","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/oli.2009.0216","article-title":"Physiologically based pharmacokinetics of molecular imaging nanoparticles for mRNA detection determined in tumor-bearing mice","volume":"20","author":"Opitz","year":"2010","journal-title":"Oligonucleotides"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.impact.2020.100253","article-title":"Smart nanocarriers for cancer treatment: clinical impact and safety","volume":"20","author":"Liao","year":"2020","journal-title":"NanoImpact"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.03.010","article-title":"Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological Malignancies","volume":"24","author":"Bastin","year":"2022","journal-title":"Cytotherapy"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12010071","article-title":"DNA vaccines: their formulations, engineering and delivery","volume":"12","author":"Kozak","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","article-title":"mRNA vaccine: a potential therapeutic strategy","volume":"20","author":"Wang","year":"2021","journal-title":"Mol Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"B87","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00872-1","article-title":"The immune microenvironment of colorectal cancer","volume":"25","author":"Kennel","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3225","article-title":"Stromal gene expression defines poor-prognosis subtypes in colorectal cancer","volume":"47","author":"A","year":"2015","journal-title":"Nat Genet"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.08.013","article-title":"Dependency of colorectal cancer on a TGF-\u03b2-driven program in stromal cells for metastasis initiation","volume":"22","author":"A","year":"2012","journal-title":"Cancer Cell"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0308","article-title":"A TGF\u03b2-dependent stromal subset underlies immune checkpoint inhibitor efficacy in DNA mismatch repair\u2013deficient\/microsatellite instability-high colorectal cancer","volume":"18","author":"Endo","year":"2020","journal-title":"Mol Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Dvf","year":"2018","journal-title":"Nature"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.08.003","article-title":"Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive poor-prognosis subtypes and metastasis","volume":"36","author":"R","year":"2019","journal-title":"Cancer Cell"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31316","article-title":"Inhibition of Nox4\u2010dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal\u2010mediated protumorigenic interactions","volume":"143","author":"Sampson","year":"2018","journal-title":"Int J Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-022-01002-x","article-title":"Metabolic communication in the tumour-immune microenvironment","volume":"24","author":"Kc","year":"2022","journal-title":"Nat Cell Biol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00860-7","article-title":"Tumor hypoxia represses \u03b3\u03b4 T cell-mediated antitumor immunity against brain tumors","volume":"22","author":"Jh","year":"2021","journal-title":"Nat Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","article-title":"\u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects","volume":"613","author":"Vries","year":"2023","journal-title":"Nature"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1172\/JCI174545","article-title":"Tissue-specific reprogramming leads to angiogenic neutrophil specialization and tumor vascularization in colorectal cancer","volume":"134","author":"Tm","year":"2024","journal-title":"J Clin Invest"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2022.02.033","article-title":"Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells","volume":"82","author":"J","year":"2022","journal-title":"Mol Cell"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03045-2","article-title":"Metabolic support of tumour-infiltrating regulatory T cells by lactic acid","volume":"591","author":"Watson","year":"2021","journal-title":"Nature"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2025.149220","article-title":"Identification of lactylation-associated fibroblast subclusters predicting prognosis and cancer immunotherapy response in colon cancer","volume":"940","author":"Liang","year":"2025","journal-title":"Gene"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.0c05039","article-title":"In situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy","volume":"21","author":"Yin","year":"2021","journal-title":"Nano Lett"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425656","article-title":"Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA","volume":"35","author":"Scheel","year":"2005","journal-title":"Eur J Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/ni1087","article-title":"The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses","volume":"5","author":"Yoneyama","year":"2004","journal-title":"Nat Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002293","article-title":"Toll-like receptor 7 controls the anti-retroviral germinal center response","volume":"7","author":"Browne","year":"2011","journal-title":"PloS Pathog"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350437","article-title":"B cell-intrinsic TLR7 signaling is required for neutralizing antibody responses to SARS-CoV-2 and pathogen-like COVID-19 vaccines","volume":"53","author":"Miquel","year":"2023","journal-title":"Eur J Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12964-024-01601-1","article-title":"MiR-574-5p activates human TLR8 to promote autoimmune signaling and lupus","volume":"22","author":"Wang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B109","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri1337","article-title":"TLR ligands from the natural world","volume":"4","author":"Honey","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.micinf.2012.10.008","article-title":"Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response","volume":"15","author":"Li","year":"2013","journal-title":"Microbes Infection"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/ni1223","article-title":"Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1\u2013polarizing program in dendritic cells","volume":"6","author":"Napolitani","year":"2005","journal-title":"Nat Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41541-022-00523-8","article-title":"TLR agonists induce sustained IgG to hemagglutinin stem and modulate T cells following newborn vaccination","volume":"7","author":"Clemens","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B113","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B114","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature14320","article-title":"Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients","volume":"519","author":"Mitchell","year":"2015","journal-title":"Nature"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.03.011","article-title":"mRNA cancer vaccines: Advances, trends and challenges","volume":"12","author":"He","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2957","article-title":"Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy","volume":"72","author":"Van Lint","year":"2012","journal-title":"Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl072","article-title":"Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests","volume":"17","author":"Wj","year":"2006","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.141226398","article-title":"Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy","volume":"98","author":"L","year":"2001","journal-title":"PNAS"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer neoantigens","volume":"37","author":"Tn","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat1435","article-title":"The immune system profoundly restricts intratumor genetic heterogeneity","volume":"3","author":"Milo","year":"2018","journal-title":"Sci Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c20535","article-title":"Dual-targeting mRNA cancer vaccines for simultaneous antigen presentation in dendritic and tumor cells","volume":"20","author":"Kim","year":"2026","journal-title":"ACS Nano"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.101965","article-title":"Lipid-encapsulated mRNA encoding an extended serum half-life interleukin-22 ameliorates metabolic disease in mice","volume":"86","author":"Canali","year":"2024","journal-title":"Mol Metab"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14583","article-title":"Preliminary safety, antitumor activity, and pharmacodynamics of intratumoral ABO2011 (IL-12 mRNA) in patients with advanced solid tumors","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.55563\/clinexprheumatol\/a9hrmo","article-title":"Macrophage activation syndrome after BNT162b2 mRNA vaccination successfully treated with corticosteroids","volume":"40","author":"Ashizawa","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101801","article-title":"A pH\/MMP-9 smart dual-responsive liposome GBE@LP co-delivers and controls the release of GB1107\/BMS1166\/Enzalutamide for liver cancer immunotherapy","volume":"32","author":"Lu","year":"2025","journal-title":"Mater Today Bio"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.4c07684","article-title":"Bacterial lysate-based bifunctional mRNA nanoformulation for efficient colon cancer immunogene therapy","volume":"16","author":"X","year":"2024","journal-title":"ACS Appl Materials Interfaces"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B129","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrc3246","article-title":"The determinants of tumour immunogenicity","volume":"12","author":"Blankenstein","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200978","article-title":"Shared neoantigens for cancer immunotherapy","volume":"33","author":"Goloudina","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102383","article-title":"The current clinical landscape of personalized cancer vaccines","volume":"106","author":"Fritah","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05780-2","article-title":"Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0","volume":"49","author":"Lopci","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat Med"},{"key":"B134","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211\u201301 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12111270","article-title":"Immune checkpoint inhibitors and vaccination: assessing safety, efficacy, and synergistic potential","volume":"12","author":"New","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7048","article-title":"Immune-related adverse events among COVID-19\u2013vaccinated patients with cancer receiving immune checkpoint blockade","volume":"20","author":"Widman","year":"2022","journal-title":"J Natl Compr Cancer Network"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adu6730","article-title":"Vaccination-induced T cell responses maintain polyclonality with high antigen receptor avidity","volume":"10","author":"Kocher","year":"2025","journal-title":"Sci Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA13","article-title":"A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC)","volume":"43","author":"Hecht","year":"2025","journal-title":"J Clin Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013766","article-title":"Reframing adjuvant immunotherapy in melanoma: all of it starts with priming","volume":"13","author":"Ascierto","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","article-title":"RNA circularization diminishes immunogenicity and can extend translation duration in vivo","volume":"74","author":"Wesselhoeft","year":"2019","journal-title":"Mol Cell"},{"key":"B142","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molcel.2019.07.016","article-title":"N6-methyladenosine modification controls circular RNA immunity","volume":"76","author":"Chen","year":"2019","journal-title":"Mol Cell"},{"key":"B143","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.molcel.2021.11.019","article-title":"RNA circles with minimized immunogenicity as potent PKR inhibitors","volume":"82","author":"Liu","year":"2022","journal-title":"Mol Cell"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01097-x","article-title":"Recent advances and perspectives on the development of circular RNA cancer vaccines","volume":"10","author":"Gong","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"B146","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33115","article-title":"Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors","volume":"147","author":"Salem","year":"2020","journal-title":"Int J Cancer"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2503","article-title":"Germline mutations in the proof-reading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas","volume":"45","author":"Palles","year":"2013","journal-title":"Nat Genet"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4846","article-title":"Identifying tumor antigens and immuno\u2010subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine","volume":"11","author":"Tan","year":"2022","journal-title":"Cancer Med"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-bsgcampus.15","article-title":"O15 evolutionary characteristics of neoantigens in inflammatory bowel disease and colorectal cancer","volume":"70","author":"Stanley","year":"2021","journal-title":"Gut"},{"key":"B153","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1200\/JCO.2026.44.2_suppl.196","article-title":"The interplay of HLA diversity and copy loss, T-cell profiles, and immunotherapy efficacy in colorectal adenocarcinoma","volume":"44","author":"Galbraith","year":"2026","journal-title":"J Clin Oncol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00446-6","article-title":"Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial","volume":"23","author":"Yamazaki","year":"2022","journal-title":"Lancet Oncol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1241208","article-title":"It\u2019s high-time to re-evaluate the value of induced-chemotherapy for reinforcing immunotherapy in colorectal cancer","volume":"14","author":"Yao","year":"2023","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2022.01.004","article-title":"Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer","volume":"40","author":"Nicolas","year":"2022","journal-title":"Cancer Cell"},{"key":"B159","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1186\/s12885-019-5909-5","article-title":"Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness","volume":"19","author":"Bencsikova","year":"2019","journal-title":"BMC Cancer"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13036-025-00573-1","article-title":"Integration of TLR7\/8 agonists into lipid nanoparticles enhances antigen-specific immune responses to N1-methyl-\u03a8-modified mRNA-LNP vaccines","volume":"19","author":"Choi","year":"2025","journal-title":"J Biol Eng"},{"key":"B162","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"B165","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jconrel.2024.11.023","article-title":"Preclinical development of lyophilized self-replicating RNA vaccines for COVID-19 and malaria with improved long-term thermostability","volume":"377","author":"Gulati","year":"2025","journal-title":"J Control Release"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf4100","article-title":"Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2","volume":"15","author":"Stewart-Jones","year":"2023","journal-title":"Sci Transl Med"},{"key":"B167","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","article-title":"Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study","volume":"3","author":"K\u00fcbler","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B168","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1246682","article-title":"Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1778522\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:56:11Z","timestamp":1778219771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1778522\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":169,"alternative-id":["10.3389\/fimmu.2026.1778522"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1778522","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1778522"}}